WO2008146914A1 - Heterocyclic compound - Google Patents

Heterocyclic compound Download PDF

Info

Publication number
WO2008146914A1
WO2008146914A1 PCT/JP2008/060028 JP2008060028W WO2008146914A1 WO 2008146914 A1 WO2008146914 A1 WO 2008146914A1 JP 2008060028 W JP2008060028 W JP 2008060028W WO 2008146914 A1 WO2008146914 A1 WO 2008146914A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
ring
alkoxy
useful
heterocyclic group
Prior art date
Application number
PCT/JP2008/060028
Other languages
French (fr)
Japanese (ja)
Inventor
Shigeru Furukubo
Hiroshi Miyazaki
Tatsuo Nakajima
Yousuke Ikeda
Kenji Morokuma
Chihiro Nakamaki
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of WO2008146914A1 publication Critical patent/WO2008146914A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound represented by the formula: (I) (wherein the ring A represents pyrimidine or the like, the ring B represents a carbocyclic ring which may be substituted, an aromatic heterocyclic ring which may be substituted or an alicyclic heterocyclic ring which may be substituted, the ring C represents an aromatic carbocyclic ring which may be substituted, X represents a single bond or alkylene, R1 represents a heterocyclic group which may be substituted or heterocyclic group-substituted alkoxy or the like, R2 represents hydrogen, alkyl, haloalkyl, alkoxy, alkanoyl, cyano, carbamoyl, alkoxycarbonyl, halogen or the like, m represents 1 or 2) or a pharmaceutically acceptable salt thereof is useful as a CCR4 function regulator useful for preventing or treating a disease such as bronchial asthma or atopic dermatitis.
PCT/JP2008/060028 2007-06-01 2008-05-30 Heterocyclic compound WO2008146914A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-147090 2007-06-01
JP2007147090A JP2010208945A (en) 2007-06-01 2007-06-01 Heterocyclic compound

Publications (1)

Publication Number Publication Date
WO2008146914A1 true WO2008146914A1 (en) 2008-12-04

Family

ID=40075144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060028 WO2008146914A1 (en) 2007-06-01 2008-05-30 Heterocyclic compound

Country Status (2)

Country Link
JP (1) JP2010208945A (en)
WO (1) WO2008146914A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079118A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc Pteridinones as inhibitors of polo-like kinase
JP2013508328A (en) * 2009-10-21 2013-03-07 エフ．ホフマン−ラ ロシュ アーゲー Diazepan derivatives as modulators of chemokine receptors
JP2015500240A (en) * 2011-12-01 2015-01-05 ケモセントリックス，インコーポレイティド Substituted benzimidazoles and benzopyrazoles as CCR (4) antagonists
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN104672147A (en) * 2015-02-17 2015-06-03 衢州学院 Preparation method of 2,4-dyhydroxyl-5-pyrimidinecarboxylic acid
EP2473486B1 (en) 2009-09-02 2015-10-28 Vifor (International) Ag Pyrimidines as hepcidine antagonists
WO2019147862A1 (en) * 2018-01-26 2019-08-01 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JP2019525962A (en) * 2016-07-29 2019-09-12 ラプト・セラピューティクス・インコーポレイテッド Chemokine receptor modulator and use thereof
CN115043780A (en) * 2022-07-11 2022-09-13 上海飞琰化工科技有限公司 Synthesis method and application of 4-hydroxy-5-fluoro-6-ethylpyrimidine
EP3929198A4 (en) * 2019-02-19 2022-11-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
WO2023143194A1 (en) * 2022-01-25 2023-08-03 瑞石生物医药有限公司 Ccr4 small molecule antagonist and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598387B2 (en) 2012-10-11 2017-03-21 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
CA2896731A1 (en) * 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011442A1 (en) * 2002-07-29 2004-02-05 Shizuoka Coffein Co., Ltd. Pyrimidine derivatives
WO2004074260A1 (en) * 2003-02-21 2004-09-02 Kyowa Hakko Kogyo Co., Ltd. Pyrimidine derivatives
WO2005082865A1 (en) * 2004-02-27 2005-09-09 Astellas Pharma Inc. Fused bicyclic pyrimidine derivative
WO2005085212A1 (en) * 2004-03-04 2005-09-15 Astellas Pharma Inc. Substituted pyrimidine derivative
WO2006004776A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 4-pyrimidineamine compounds and their uses as anti-proliferative agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011442A1 (en) * 2002-07-29 2004-02-05 Shizuoka Coffein Co., Ltd. Pyrimidine derivatives
WO2004074260A1 (en) * 2003-02-21 2004-09-02 Kyowa Hakko Kogyo Co., Ltd. Pyrimidine derivatives
WO2005082865A1 (en) * 2004-02-27 2005-09-09 Astellas Pharma Inc. Fused bicyclic pyrimidine derivative
WO2005085212A1 (en) * 2004-03-04 2005-09-15 Astellas Pharma Inc. Substituted pyrimidine derivative
WO2006004776A1 (en) * 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. 4-pyrimidineamine compounds and their uses as anti-proliferative agents

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473486B1 (en) 2009-09-02 2015-10-28 Vifor (International) Ag Pyrimidines as hepcidine antagonists
JP2013508328A (en) * 2009-10-21 2013-03-07 エフ．ホフマン−ラ ロシュ アーゲー Diazepan derivatives as modulators of chemokine receptors
WO2011079118A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc Pteridinones as inhibitors of polo-like kinase
WO2011079114A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc. Pteridinones as inhibitors of polo - like kinase
CN102762568A (en) * 2009-12-23 2012-10-31 伊兰药品公司 Pteridinones as inhibitors of polo - like kinase
JP2013515734A (en) * 2009-12-23 2013-05-09 エラン ファーマシューティカルズ，インコーポレイテッド Pteridinone as an inhibitor of polo-like kinases
US8445503B2 (en) 2009-12-23 2013-05-21 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
US8541418B2 (en) 2009-12-23 2013-09-24 Elan Pharmaceutical, Inc. Inhibitors of polo-like kinase
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
JP2015500240A (en) * 2011-12-01 2015-01-05 ケモセントリックス，インコーポレイティド Substituted benzimidazoles and benzopyrazoles as CCR (4) antagonists
CN104672147A (en) * 2015-02-17 2015-06-03 衢州学院 Preparation method of 2,4-dyhydroxyl-5-pyrimidinecarboxylic acid
JP2019525962A (en) * 2016-07-29 2019-09-12 ラプト・セラピューティクス・インコーポレイテッド Chemokine receptor modulator and use thereof
AU2019212478C1 (en) * 2018-01-26 2023-11-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
US10683280B2 (en) 2018-01-26 2020-06-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
CN111971279A (en) * 2018-01-26 2020-11-20 拉普特医疗公司 Chemokine receptor modulators and uses thereof
US11192879B2 (en) 2018-01-26 2021-12-07 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
US11384064B2 (en) 2018-01-26 2022-07-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
AU2019212478B2 (en) * 2018-01-26 2023-02-23 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
WO2019147862A1 (en) * 2018-01-26 2019-08-01 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
TWI826416B (en) * 2018-01-26 2023-12-21 美商瑞佩特治療公司 Chemokine receptor modulators and uses thereof
US12098139B2 (en) 2018-01-26 2024-09-24 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
EP3929198A4 (en) * 2019-02-19 2022-11-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
WO2023143194A1 (en) * 2022-01-25 2023-08-03 瑞石生物医药有限公司 Ccr4 small molecule antagonist and use thereof
CN115043780A (en) * 2022-07-11 2022-09-13 上海飞琰化工科技有限公司 Synthesis method and application of 4-hydroxy-5-fluoro-6-ethylpyrimidine
CN115043780B (en) * 2022-07-11 2024-01-16 上海飞琰化工科技有限公司 Synthesis method and application of 4-hydroxy-5-fluoro-6-ethylpyrimidine

Also Published As

Publication number Publication date
JP2010208945A (en) 2010-09-24

Similar Documents

Publication Publication Date Title
WO2008146914A1 (en) Heterocyclic compound
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
MY150507A (en) Polycyclic compound
MY148703A (en) Polycyclic cinnamide derivatives
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
WO2006030977A3 (en) Imidazole derivatives as large conductance calcium-activated k channel openers
WO2005103037A3 (en) Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
WO2008096829A1 (en) Tricyclic compounds
AU2008255733A8 (en) Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2007061923A3 (en) Glucokinase activators
WO2008146665A1 (en) Material for organic electroluminescent device, organic electroluminescent device, and organic electroluminescent display device
WO2009019015A8 (en) Novel herbicides
WO2009065920A3 (en) Compounds
WO2007000339A8 (en) Bicyclic derivatives as p38 kinase inhibitors
EP1867331A4 (en) Triazole derivative and the use thereof
EP1726584A4 (en) 2-aminoquinazoline derivative
WO2005115984A3 (en) Large conductance calcium-activitated k channel opener
WO2009057784A1 (en) Heterocyclic compound
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2009018065A3 (en) Novel glucokinase activators and methods of using same
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2006023889A3 (en) A method for preparing irbesartan and intermediates thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777039

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777039

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP